Question

Difficulty: HardOrdering Laboratory Tests

A 3434-year-old woman is referred to the endocrinology clinic due to unexplained weight gain of 1515 kg over the past year, accompanied by easy bruising and new-onset facial hair growth. She reports that her menstrual periods, previously regular, now occur only once every 33 to 44 months. Vital signs show a blood pressure of 158/98158/98 mm Hg. Physical examination is notable for facial plethora, a dorsocervical fat pad, truncal obesity with thin extremities, and wide, purplish striae over the lower abdomen and flanks. The physician suspects hypercortisolism. Assuming the patient ultimately has a pituitary adenoma (Cushing disease) and each successive diagnostic test dictates the need for further localization, arrange the following laboratory tests and diagnostic procedures in the correct sequential order from initial screening to definitive confirmation.

  1. 12424-hour urine free cortisol measurement
  2. 2Plasma adrenocorticotropic hormone (ACTH) assay
  3. 3High-dose (88-mg) dexamethasone suppression test
  4. 4Inferior petrosal sinus sampling (IPSS)

Answer

The correct sequence is: 2424-hour urine free cortisol measurement, followed by Plasma ACTH assay, then High-dose (88-mg) dexamethasone suppression test, and finally Inferior petrosal sinus sampling (IPSS).
The diagnosis of Cushing syndrome follows a strict sequential algorithm to minimize false positives and avoid unnecessary invasive testing. First, endogenous hypercortisolism must be confirmed with a primary screening test, such as the 2424-hour urine free cortisol measurement, late-night salivary cortisol, or a low-dose dexamethasone suppression test. Once hypercortisolism is established, the second step is measuring plasma ACTH to differentiate ACTH-independent (adrenal) from ACTH-dependent (pituitary/ectopic) causes. Third, if the condition is ACTH-dependent, a high-dose (88-mg) dexamethasone suppression test is used to distinguish a pituitary adenoma (which usually suppresses) from an ectopic ACTH-secreting tumor (which typically does not suppress). Finally, if non-invasive tests and imaging are equivocal, inferior petrosal sinus sampling (IPSS) is performed to definitively confirm a central pituitary source of ACTH.

Step-by-Step Solution

1
Confirm the presence of hypercortisolism.
Order a 2424-hour urine free cortisol measurement.
To avoid unnecessary downstream localization testing, biochemical confirmation of endogenous hypercortisolism using a first-line screening test is the mandatory first step.
2
Determine ACTH dependence.
Order a plasma ACTH assay.
Once hypercortisolism is confirmed, measuring ACTH differentiates between ACTH-independent (adrenal tumors) and ACTH-dependent (pituitary or ectopic) sources.
3
Differentiate ACTH-dependent sources.
Order a high-dose (88-mg) dexamethasone suppression test.
Pituitary adenomas typically retain some negative feedback and will suppress cortisol production at high dexamethasone doses, whereas ectopic ACTH-producing tumors typically do not suppress.
4
Confirm pituitary lateralization and source invasively.
Order inferior petrosal sinus sampling (IPSS).
If non-invasive biochemical tests are equivocal or discordant with pituitary magnetic resonance imaging, IPSS directly measures the central-to-peripheral ACTH gradient to definitively confirm Cushing disease.

Key Concept

The sequential diagnostic evaluation of Cushing syndrome begins with confirming hypercortisolism, followed by determining ACTH dependence, differentiating the ACTH source using high-dose suppression testing, and ultimately using invasive sampling if non-invasive localization is equivocal.
Estimated Time:1m 30s
Rate this question